Epigenetic priming with oral decitabine/cedazuridine com-bined with nivolumab in unresectable or metastatic mucosal melanoma: Clinical and correlative findings from a phase Ib/II trial

Résumé fourni par la source

This record contains the supplemental files for "Epigenetic priming with oral decitabine/cedazuridine combined with nivolumab in unresectable or metastatic mucosal melanoma: clinical and correlative findings for a phase Ib/II trial". Content overview: NCCN-Supplementary Tables - 8_25_26.pdf contains flow cytometry panels, summary statistics of Log-transformed values of pre- and on-treatment circulating immune cells, summary statistics of Log-transformed values of circulating immune cells comparing responders and non-responders, summary statistics of Log-transformed values of pre- and on-treatment tumor cells, summary statistics of original scale values of tumor cells comparing responders and non-responders, summary statistics of log-transformed values comparing responders and non-responders, representativeness of study participants. 2026-04024 Supplementary Appendix 1 - Study Protocol.pdf contains protocol amendment changes and summary, study introduction and background, objectives and endpoints, study design, study population, study intervention, discontinuation and participant withdrawal, study assessments and procedures, statistical considerations, supporting documentation and operational considerations, and references

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.